SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Longer term short term day trades.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Graustus
From: Steve Felix3/12/2023 2:44:30 PM
1 Recommendation   of 1918
 
Cash $366.

Out -$55
03/10/2023 12:29:36 Sold 400 RAVE @ 1.4901 595.98

Now 600
03/10/2023 09:46:39 Bought 50 ASRT @ 6.28 -314.00
03/10/2023 12:36:06 Bought 50 ASRT @ 6.0992 -304.96

Now $657
03/10/2023 10:41:20 Bought 25 SPRY @ 8.63 -215.75
03/10/2023 12:42:26 Bought 25 SPRY @ 8.53 -213.25
03/10/2023 14:14:58 Bought 10 SPRY @ 8.08 -80.80
03/10/2023 15:40:34 Bought 100 SPRY @ 7.97 -797.00

Out -$135
03/10/2023 15:39:35 Sold 375 BKTI @ 3.0646 1,149.17


Hesitate to comment for fear someone takes something as a rec, but going to comment on why I am
buying SPRY on this down move. Biotechs are tough. Their drugs fail, and they drop like a rock.
They seem full of promise shorter term, and then things take years instead of months. They begin
a move up, just to issue millions of shares. Caveat emptor.

Spry has $250 million in cash. They recently filed a new drug application: "The FDA has assigned a
prescription drug user fee act target action date that is expected in mid-2023, Silverback Therapeutics said."

IF IF IF their epinephrine nasal spray gets the ok, it could be a game changer.

My grand daughter has had two reactions where she was taken to the emergency room. The second
time they were sent home with an EpiPen. Noboby wants to use it, but will if we have too. My daughter,
and many others I am sure, would love to buy this if it gets the ok.

According to the company, this works like Narcan, with no inhalation necessary.

With biotechs I always figure the odds are against me, so this is only .005% of portfolio.

Their latest powerpoint: ir.ars-pharma.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News